



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Robert M. LORENCE et al

Serial No. 08/260,536

Filed: June 16, 1994

Atty. Ref.: 2370-11

TC/A.U.: 1648

Examiner: Le, Emily M.

For: METHODS FOR TREATING AND DETECTING CANCER USING
VIRUSES

* * * * *

October 18, 2004

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449.


This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lfm

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

10/19/2004 SSESHE1 00000154 08260536 180.00 DP
01 FC:1806

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT


Robert M. LORENCE et al

FILING DATE

TC/A.U.

June 16, 1994

1648



(Use General sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Povlsen, C.O.; "Status of Chemotherapy, Radiotherapy, Endocrine Therapy, and Immunotherapy Studies of Human Cancer in the Nude Mouse"; <i>The Nude Mouse in Experimental and Clinical Research</i> ; Academic Press, New York, San Francisco, London; pp. 437-457 (1978).
	Thorne, S.H., et al; "Future Directions for the Field of Oncolytic Virotherapy: A Perspective on the Use of Vaccinia Virus"; <i>Expert Opin. Biol. Ther.</i> ; Vol. 4, No. 8; pp 1307-1321 (2004).
	Poster (ASCO Meeting); "Slow Intravenous Infusion of PV701, An Oncolytic Virus: Final Results of a Phase Study"; <i>2004 Am. Soc. Clin. Oncology (ASCO) Mtg.</i>
	Schirmacher, V., et al; "Virus Potentiation of Tumor Vaccine T-Cell Stimulatory Capacity Requires Cell Surface Binding but not Infection"; <i>Clinical Cancer Research</i> ; Vol. 3; pp. 1135-1148 (1997).
	Zorn, U., et al; "Induction of Cytokines and Cytotoxicity Against Tumor Cells by Newcastle Disease Virus"; <i>Cancer Biotherapy</i> ; Vol. 9, No. 3; pp. 225-235 (1994).
	Zorn, U., et al; "Active Specific Immunotherapy of Renal Cell Carcinoma: Cellular and Humoral Immune Responses"; <i>Cancer Biotherapy & Radiopharmaceuticals</i> ; Vol. 12, No. 3; pp. 157-165 (1997).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 4; C-584 p. 150 (1985).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 5; 534 p. 137 (1986).
	Krishnamurthy, S., et al; "Newcastle Disease Virus as an Oncolytic Agent: Mechanism of Viral Infection, Growth and Oncolysis"; <i>American Society for Virology 21st Annual Meeting, University of Kentucky, Lexington, KY, July 20-24, 2002, Scientific Program and Abstracts</i> ; p. 90.
	Batliwalla, F.M., et al; "A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alternations in the CD8 T Cell Repertoire"; <i>Molecular Medicine</i> ; Vol. 4; pp. 783-794 (1998).
	Bonaccorsi, P., et al; "Management of High-risk Melanoma"; <i>Medical Dermatology</i> ; Vol. 19, No. 4; pp 727-735 (2001).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.